Oncotarget

Clinical Research Papers:

IL-18 polymorphisms contribute to hepatitis B virus-related cirrhosis and hepatocellular carcinoma susceptibility in Chinese population: a case-control study

Zhi-Jun Dai, Xing-Han Liu, Meng Wang, Yan Guo, Wenge Zhu, Xiao Li, Shuai Lin, Tian Tian, Kang Liu, Yi Zheng, Peng Xu, Tianbo Jin and Xiaopeng Li _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:81350-81360. https://doi.org/10.18632/oncotarget.18531

Metrics: PDF 1076 views  |   HTML 1768 views  |   ?  


Abstract

Zhi-Jun Dai1,*, Xing-Han Liu1,*, Meng Wang1,*, Yan Guo2, Wenge Zhu3, Xiao Li4, Shuai Lin1, Tian Tian1, Kang Liu1, Yi Zheng1, Peng Xu1, Tianbo Jin5 and Xiaopeng Li6

1Department of Oncology, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China

2School of Life Science and Technology, Xi’an Jiaotong University, Xi’an, China

3Department of Biochemistry and Molecular Medicine, The George Washington University Medical School, Washington, DC, USA

4Department of Hepatobiliary Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, China

5National Engineering Research Center for Miniaturized Detection Systems, School of Life Sciences, Northwest University, Xi’an, China

6Department of Ultrasound, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China

*These authors contributed equally to this work

Correspondence to:

Xiaopeng Li, email: xiaopengli8@126.com

Zhi-Jun Dai, email: dzj0911@126.com

Keywords: IL-18, HBV, susceptibility

Received: February 24, 2017     Accepted: June 04, 2017     Published: June 17, 2017

ABSTRACT

IL-18 polymorphisms influence the transcriptional activity of the IL-18 gene and associated with various diseases. However, their relationships with hepatitis B virus-related liver diseases had not reached a consensus. So we conducted this case-control study with a view to clarifying the association. We included four groups: healthy controls, chronic hepatitis B virus (CHB) carriers, liver cirrhosis (LC) and hepatocellular carcinoma (HCC) groups with each group of 250 persons. Odd ratios (ORs) and 95% confidence intervals (95%CIs) with or without adjustment were calculated. Haplotype analysis was also performed. The results showed people carrying rs187238 CG genotype had a lower risk of LC (CG vs. CC: OR = 0.59, 95%CI = 0.38–0.91, P = 0.02), while GG genotype carriers had a higher risk of HCC (GG vs. CC+CG: OR = 4.73, 95%CI = 1.01–22.1, P = 0.03) than those with CC and CG genotypes in healthy group. Rs187238 GG genotype increased the risk from CHB to LC status (GG vs. CC: OR = 4.81, 95%CI = 1.03–22.6; GG vs. CC+CG: OR = 4.73, 95%CI = 1.01–22.1), meanwhile the trend also existed by controlling confounding factors (GG vs. CC: OR = 6.25, 95%CI = 1.09–35.8; GG vs. CC+CG: OR = 5.91, 95%CI = 1.04–33.7). Haplotype Crs187238Trs1946518 moderately decreased the risk of CHB carriers developing into HCC (OR = 0.69, 95%CI = 0.50–0.96, P = 0.03) after adjustment. In conclusion, IL-18 rs187238 GG genotype may increase the risk of HCC in healthy population and the risk of LC in CHB carriers.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 18531